Azacitidine plus Venetoclax versus Azacitidine for AML maintenance
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether adding venetoclax (a cancer drug) to azacitidine (a chemotherapy) works better than azacitidine alone for patients with acute myeloid leukemia (AML) in first remission. The goal is to prevent the cancer from returning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML or a related blood cancer (MDS/AML) that meets WHO or ICC diagnostic criteria
- You are between 14 and 75 years old
- You are in first complete remission or near-complete remission after induction and consolidation chemotherapy
- You received at least 2 cycles of intermediate- or high-dose cytarabine chemotherapy
- You enrolled within 10 months of first remission and within 3 months of your last treatment
- Your cancer shows no detectable or very low levels of minimal residual disease (MRD); you cannot have high MRD
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests whether azacitidine (CC-486) plus venetoclax can help people with acute myeloid leukemia (AML) that is not APL. It’s designed to find safe dosing and see how well the combination works for newly diagnosed or relapsed/refractory AML.
This trial tests a combination of three drugs (venetoclax, azacitidine, and liposomal mitoxantrone) as a first treatment for people newly diagnosed with acute myeloid leukemia (AML). The goal is to see if this combination works better than standard care.
This trial studies azacytidine (AZA) plus venetoclax as maintenance treatment to help keep acute myeloid leukemia (AML) in first remission. It may help delay or prevent AML from returning in younger adults who cannot get a stem cell transplant right away.
This trial studies whether adding venetoclax to either azacitidine or decitabine can treat acute myeloid leukemia (AML) when earlier “hypomethylating” treatment has stopped working. You might be a candidate if you’ve already tried azacitidine or decitabine for a related blood condition and it failed, and you meet the health-safety limits.
This Phase 2 trial compares two treatment approaches for people newly diagnosed with a specific type of AML (bone marrow cancer) that has an NPM1 mutation: venetoclax plus azacitidine versus intensive (strong) chemotherapy. It aims to see which plan works better and is safer for “fit” patients.
This trial tests a combination of oral venetoclax and injected azacitidine for adults who are newly diagnosed with acute myeloid leukemia (AML) and cannot have standard strong chemotherapy. The goal is to see how well this treatment works and what side effects it may cause.
Hear when a new AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.